CaroGen
company
About
CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $1.40M
- Industries
- Biopharma,Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2012
- Number Of Employee
- 1 - 10
- Operating Status
- Active
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new platform technology developed by Professor John Rose at Yale University School of Medicine. We are dedicated to creating recombinant and replication proficient-virus like vesicle (VLV)-based vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$1.40M
CaroGen has raised a total of
$1.40M
in funding over 2 rounds. Their latest funding was raised on
Mar 27, 2019 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 27, 2019 | Grant | $1.40M | 1 |
National Institutes of Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
CaroGen is funded by 1 investors.
National Institutes of Health
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
